ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

Key facts

Sponsor

Philipps University Marburg

Principal Investigator

Andreas Burchert, Prof. Dr.

Philipps University Marburg

Intervention

AOP2014 / Pegylated-Proline-interferon alpha-2b(drug)

Enrollment

214 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2022

Study locations (26)

• Institut Bergonié, Bordeaux, France
• Centre Léon Bérard, Lyon, France
• CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
• 03 Universitätsklinikum Aachen, Hämatologie/Onkologie, Aachen, Germany
• 18 Studienzentrum Aschaffenburg, Aschaffenburg, Germany
• 06 Universitätsmedizin Berlin Charite- Campus Virchow Klinikum, Klinik für Hämatologie und Onkologie, Berlin, Germany
• 19 Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Bonn, Germany
• 16 Klinikum Bremen Mitte, Medizinische Klinik I, Bremen, Germany
• 22 BAG / Onkologische Gemeinschaftspraxis, Dresden, Germany
• 05 Universitätsklinikum Düsseldorf, Klinik für Hämatologie, Onkologie und Klinische Immunologie, Düsseldorf, Germany
• 07 Universitätsklinikum Erlangen, Medizinische Klinik 5, Erlangen, Germany
• 20 Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany
• 17 Klinikum der Goethe Universität, Medizinische Klinik II, Frankfurt A. Main, Germany
• 21 Universitätsklinikum Hamburg Eppendorf, Klinik für Onkologie, Hämatologie und KMT, Hamburg, Germany
• 23 Evangelische Krankenhaus Hamm gGmbH, Klinik für Hämatologie, Onkologie und Palliativmedizin, Hamm, Germany
• +11 more locations on ClinicalTrials.gov

Collaborators

Deutsche Krebshilfe e.V., Bonn (Germany) · AOP Orphan Pharmaceuticals AG

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07354074
  Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
  Novartis Pharmaceuticals
• RECRUITINGNCT07375355
  Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
  Novartis Pharmaceuticals
• ENROLLING BY INVITATIONNCT07383298
  Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
  Qian Jiang
• RECRUITINGPHASE2NCT06817720
  Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
  M.D. Anderson Cancer Center
• RECRUITINGNCT07061145
  A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
  Azienda USL Reggio Emilia - IRCCS
• RECRUITINGPHASE2NCT06409936
  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
  Gruppo Italiano Malattie EMatologiche dell'Adulto
• RECRUITINGPHASE2NCT06514534
  Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
  Novartis Pharmaceuticals
• RECRUITINGPHASE1NCT06787144
  ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
  Enliven Therapeutics

See all trials for Chronic myeloid leukemia →